Endocrinology & metabolism

August 1997
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS20
Academic Journal
Presents an abstract of the research manuscript `Do ace inhibitors prevent progression of renal disease in diabetics with microalbuminuria: A meta-analysis of randomised controlled trials,' by A. Haider, P.M. Peloso and M.A. Boctor from the University of Saskatchewan.


Related Articles

  • Use of ACE inhibitors in diabetic and nondiabetic patients with renal disease. Chandramouli, Jane Blayney; Stokes, John B. // Formulary;Apr98, Vol. 33 Issue 4, p318 

    Provides information on the therapeutic use of angiotensin-converting enzyme (ACE) inhibitors in retarding the progression of renal disease of diabetic and nondiabetic patients. Pathogenesis and risk factors of diabetic nephropathy; Effectivity of ACE on the disease; Cautions on the use of ACE...

  • To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. Clark, William F.; Churchill, David N.; Forwell, Lorie; Macdonald, Graeme; Foster, Susan // CMAJ: Canadian Medical Association Journal;1/25/2000, Vol. 162 Issue 2, p195 

    AbstractBackground: Angiotensin-converting-enzyme (ACE) inhibitor therapy can significantly delay the progression of diabetic nephropathy to end-stage renal failure (ESRF). The main obstacle to successful compliance with this therapy is the cost to the patients. The authors performed a...

  • Dual blockade of the renin–angiotensin system: are two better than one? Haynes, Richard; Mason, Philip; Rahimi, Kazem; Landray, Martin J. // Nephrology Dialysis Transplantation;Dec2009, Vol. 24 Issue 12, p3602 

    The article discusses the findings of studies designed to determine the effect of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) in reducing blood pressure. In a review of randomized trials, combining ARB and ACEi effectively reduced blood pressure. In a...

  • Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies—the effect on podocytes. Nemeth, Zalan; Kokeny, Gabor; Godo, Maria; Mózes, Miklós; Rosivall, László; Gross, Marie-Luise; Ritz, Eberhard; Hamar, Péter // Nephrology Dialysis Transplantation;Dec2009, Vol. 24 Issue 12, p3640 

    Background. Blockade of the renin–angiotensin–aldosterone system (RAAS) does not completely prevent progression of renal disease. Mineralocorticoid receptor blockade provides additional renoprotection over ACE-inhibition monotherapy. We examined the mechanisms underlying superior...

  • Nitrendipine and enalapril in the treatment of diabetic hypertensive patients with microalbuminuria. PIÑOL, CARME; COBOS, ALBERTO; CASES, ALEIX; ESMATGES, ENRIC; SOLER, JOSEP; CLOSAS, JOSEP; PASCUAL, RAMÓN; PLANAS, JAUME // Kidney International Supplement;Jun1996, Issue 55, pS-85 

    A trial to study the efficacy, safety and tolerability of nitrendipine and enalapril in the treatment of diabetic hypertensive patients with microalbuminuria (MA) was performed to compare the effects of both drugs in the prevention of the renal impairment. Twenty-eight valid patients [13 with...

  • New paradigms in managing chronic kidney disease. Link, Denise Keller // Clinical Advisor;Jan2013, Vol. 16 Issue 1, p18 

    The article discusses the new paradigms in managing chronic kidney disease (CKD). It is important for primary-care clinicians to identify, screen, and treat individuals to slow the progression to end-stage renal disease. The author uses clinical scenario of a patient to show the steps for...

  • ACE inhibitor cough. P.F.C. // Cortlandt Forum;5/25/96, Vol. 9 Issue 5, p115 

    Gives information on the effects of angiotensin-converting enzymes on diabetics.

  • Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. MOSCONI, LIDIA; RUGGENENTI, PIERO; PERNA, ANNALISA; MECCA, GIULIANO; REMUZZI, GIUSEPPE // Kidney International Supplement;Jun1996, Issue 55, pS-91 

    The effects of 3, 15, and 27 months of treatment with nitrendipine (10 to 40 mg/day) and enalapril (5 to 20 mg/day) on diastolic blood pressure (DBP), overnight urinary albumin excretion (UAE) rate, glomerular filtration rate (GFR), and renal plasma flow (RPF) were studied prospectively in a...

  • In this Issue.  // Kidney International;Aug2008, Vol. 74 Issue 3, p253 

    The article discusses various reports published within the issue including "Heparan Sulfate Proteycans And Albuminuria," "CXCL16 is Released by ADAM10 During Tubulointerstitial Inflammation," and "Loss of Kidney Function from Oral Estrogen Use."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics